NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Forecast, Price & News $32.09 -0.46 (-1.41%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$31.48▼$32.4550-Day Range$30.02▼$38.5952-Week Range$25.29▼$47.75Volume296,087 shsAverage Volume378,971 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$45.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PROCEPT BioRobotics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside40.2% Upside$45.00 Price TargetShort InterestBearish9.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 2 Articles This WeekInsider TradingSelling Shares$316,120 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.22) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector443rd out of 965 stocksSurgical & Medical Instruments Industry53rd out of 96 stocks 3.4 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.00, PROCEPT BioRobotics has a forecasted upside of 40.2% from its current price of $32.09.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.85% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 3.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 2.1 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PROCEPT BioRobotics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $316,120.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($2.22) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 7.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PROCEPT BioRobotics (NASDAQ:PRCT) StockPROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Read More PRCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comPROCEPT BioRobotics Announces New Corporate Headquarters in San JoseSeptember 15, 2023 | barrons.comPROCEPT BioRobotics Corp.September 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 15, 2023 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 15, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Rating Reiterated by Truist FinancialSeptember 14, 2023 | msn.comTruist Securities Reiterates Procept BioRobotics (PRCT) Buy RecommendationSeptember 12, 2023 | msn.comPROCEPT BioRobotics gets FDA okay for prostate cancer studySeptember 12, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)September 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 12, 2023 | finance.yahoo.comPROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate CancerAugust 28, 2023 | fool.comProcept BioRobotics (NASDAQ: PRCT)August 22, 2023 | finance.yahoo.comPROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in JapanAugust 17, 2023 | finance.yahoo.comPROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in BostonAugust 16, 2023 | finance.yahoo.comNorthShore University HealthSystem offers expanded access to treat most common prostate ailmentAugust 11, 2023 | msn.comPiper Sandler starts Procept at overweight, cites high growth potentialAugust 11, 2023 | msn.comPiper Sandler Initiates Coverage of Procept BioRobotics (PRCT) with Overweight RecommendationAugust 11, 2023 | markets.businessinsider.comPROCEPT BioRobotics (PRCT) Receives a New Rating from Piper SandlerAugust 11, 2023 | finance.yahoo.comTwilio upgraded, Sealed Air downgraded: Wall Street's top analyst callsAugust 11, 2023 | msn.comProcept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate BuyAugust 10, 2023 | seekingalpha.comProcept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate BuyAugust 3, 2023 | seekingalpha.comPROCEPT BioRobotics launches stock offering to raise $125MAugust 2, 2023 | finance.yahoo.comThe one-year earnings decline has likely contributed toPROCEPT BioRobotics' (NASDAQ:PRCT) shareholders losses of 14% over that periodAugust 1, 2023 | finance.yahoo.comPROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common StockAugust 1, 2023 | finance.yahoo.comPROCEPT BioRobotics Corporation Announces Proposed Offering of Common StockAugust 1, 2023 | markets.businessinsider.comPROCEPT BioRobotics (PRCT) Receives a Buy from Truist FinancialJuly 28, 2023 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)July 27, 2023 | finance.yahoo.comPROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue EstimatesSee More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRCT Company Calendar Last Earnings7/27/2023Today9/21/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees428Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.00 High Stock Price Forecast$49.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+40.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,150,000.00 Net Margins-102.87% Pretax Margin-102.87% Return on Equity-54.25% Return on Assets-34.04% Debt Debt-to-Equity Ratio0.34 Current Ratio6.40 Quick Ratio5.21 Sales & Book Value Annual Sales$75.01 million Price / Sales19.37 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book7.28Miscellaneous Outstanding Shares45,280,000Free Float36,404,000Market Cap$1.45 billion OptionableNot Optionable Beta0.57 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 68)Pres, CEO & Director Comp: $1.26MMr. Kevin Waters (Age 46)Exec. VP & CFO Comp: $744.1kMs. Alaleh Nouri (Age 44)EVP, Chief Legal Officer & Corp. Sec. Comp: $713.61kMr. Hisham Shiblaq (Age 47)Exec. VP & Chief Commercial Officer Comp: $757.2kMr. Mohan F. Sancheti (Age 59)Sr. VP of Operations Mr. Matthew James Bacso C.F.A.VP of Investor RelationsMs. Minni VittalSr. VP & Chief People OfficerMr. Bijesh ChandranSr. VP of Regulatory Affairs & Quality AssuranceMr. Barry TemplinSr. VP of Clinical & Medical AffairsDr. Thomas J. Yorkey Ph.D. (Age 61)Sr. VP of R&D More ExecutivesKey CompetitorsTandem Diabetes CareNASDAQ:TNDMAlphatecNASDAQ:ATECLeMaitre VascularNASDAQ:LMATParagon 28NYSE:FNANovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 26,106 shares on 8/21/2023Ownership: 0.101%Osaic Holdings Inc.Bought 338 shares on 8/21/2023Ownership: 0.003%Legato Capital Management LLCBought 6,770 shares on 8/18/2023Ownership: 0.015%Nuveen Asset Management LLCBought 24,275 shares on 8/16/2023Ownership: 0.211%Royal Bank of CanadaBought 1,281 shares on 8/15/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions PRCT Stock - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price forecast for 2023? 7 analysts have issued 1 year price targets for PROCEPT BioRobotics' shares. Their PRCT share price forecasts range from $42.00 to $49.00. On average, they expect the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2023? PROCEPT BioRobotics' stock was trading at $41.54 at the start of the year. Since then, PRCT stock has decreased by 22.7% and is now trading at $32.09. View the best growth stocks for 2023 here. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PRCT earnings forecast. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its quarterly earnings results on Thursday, July, 27th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.01. The firm earned $33.10 million during the quarter, compared to the consensus estimate of $30.25 million. PROCEPT BioRobotics had a negative net margin of 102.87% and a negative trailing twelve-month return on equity of 54.25%. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC) and Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ).iShares U.S. Medical Devices ETF (IHI). What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $131.00 million-$131.00 million, compared to the consensus revenue estimate of $128.50 million. When did PROCEPT BioRobotics IPO? (PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. What is PROCEPT BioRobotics' stock symbol? PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT." Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.70%), State Street Corp (2.35%), Geode Capital Management LLC (1.58%), Allspring Global Investments Holdings LLC (1.38%), Allspring Global Investments Holdings LLC (1.38%) and Mirae Asset Global Investments Co. Ltd. (1.11%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PROCEPT BioRobotics' stock price today? One share of PRCT stock can currently be purchased for approximately $32.09. How much money does PROCEPT BioRobotics make? PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.45 billion and generates $75.01 million in revenue each year. The company earns $-87,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. How many employees does PROCEPT BioRobotics have? The company employs 428 workers across the globe. How can I contact PROCEPT BioRobotics? PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com. This page (NASDAQ:PRCT) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.